Artificial intelligence—powered immune phenotyping of advanced or metastatic urothelial carcinoma clinical trial samples from hematoxylin and eosin—stained whole slide images

J. Conway,<sup>1</sup> L. Yu,<sup>1</sup> Y. Belhe,<sup>1\*</sup> S. Jain,<sup>1\*</sup> H. J. Grote,<sup>2</sup> M. Lin,<sup>1</sup> B. Trotter,<sup>1</sup> D. Sanghavi,<sup>1</sup> A. Gerhold-Ay,<sup>2</sup> X. Wang,<sup>3</sup> S. Brutus,<sup>1</sup> T. Mrowiec<sup>2</sup>



<sup>1</sup>PathAl, Boston, MA, USA; <sup>2</sup>the healthcare business of Merck KGaA, Darmstadt, Germany; <sup>3</sup>EMD Serono, Billerica, MA, USA \*Affiliation at the time the research was conducted.

# SCOPE



We report an artificial intelligence (AI)-powered approach to determine slide-level immune phenotypes directly from digitized hematoxylin and eosin (H&E)-stained whole slide images (WSI) of clinical advanced or metastatic urothelial carcinoma (UC) samples, with potential use as an alternative to CD8 immunohistochemistry (IHC)-based approaches to identify patients with hot and cold tumors

## CONCLUSIONS



An association between inflamed immune phenotypes and higher CD8 scores at the tumor core supports the potential use of this AI method as an alternative to CD8 IHC-based approaches to identify patients with hot and cold tumors in advanced or metastatic UC

### GET POSTER PDF

Copies of this poster obtained through this quick response (QR) code are for personal use only and may not be reproduced without permission from SITC and the author of this poster

Correspondence: Jake Conway, jake.conway@pathai.com; Sergine Brutus, sergine.brutus@pathai.com; Thomas Mrowiec, <u>thomas.mrowiec@emdgroup.com</u>




# BACKGROUND


- First-line (1L) maintenance with avelumab, an anti-PD-L1 antibody, combined with best supportive care (BSC) significantly prolonged overall survival vs BSC alone in the JAVELIN Bladder 100 clinical trial enrolling patients with advanced or metastatic UC that had not progressed with 1L platinum-containing chemotherapy<sup>1,2</sup>
- Results from this trial led to the approval of avelumab 1L maintenance in various countries worldwide, and the JAVELIN Bladder regimen is an established standard of care in international treatment guidelines based on level 1 evidence<sup>3-8</sup>
- PathAl machine learning (ML) models have previously been deployed to characterize the tumor microenvironment in a range of cancer types9

# METHODS

- To assess the tumor microenvironment in advanced or metastatic UC, we developed ML-based models to identify cell types and tissue regions in digitized H&E-stained WSI from the JAVELIN Bladder 100 trial. ML-quantified features were used for subsequent slide-level immune phenotyping of these clinical trial samples
- Models previously trained using samples from The Cancer Genome Atlas were refined using extensive tissue regions and cell type annotations on 703 formalin-fixed, paraffin–embedded, H&E–stained WSI scanned on MIRAX (40×) to identify artifacts, tissue regions (cancer, stroma, and necrosis), and cell types (cancer epithelial cells, lymphocytes, macrophages, fibroblasts, and granulocytes) (Figure 1). Precision, recall, and F1 scores were calculated to evaluate model performance
- In accordance with pathologist guidelines at Merck KGaA, Darmstadt, Germany, H&E slide–level digital immune phenotypes (excluded, inflamed, and desert) were determined using ML-derived features
- The distribution of H&E slide–level digital immune phenotypes was calculated across available samples in both trial arms, and the association between immune phenotype and CD8 score at the tumor core was determined using the Kruskal-Wallis and Mann-Whitney U tests

## Figure 1. Model Development





Schematic illustrating CNN model development approach for pixel-level feature predictions. CNN, convolutional neural network.

# RESULTS

- Model performance evaluation in representative frames of tissue regions that were exhaustively annotated showed high correlation of model predictions and pathologist consensus ("model vs consensus"), comparable to agreement among 5 pathologists ("annotator vs consensus") (Table 1)
- Precision, recall, and F1 scores for model predictions were comparable to those of an average annotator across cell types. The model's concordance with consensus was higher than that of an average human annotator (Cohen k, 0.816 vs 0.680) (Figure 2A and 2B)
- Calculation of the distribution of H&E slide-level digital immune phenotypes across trial arms showed that most samples in each arm were classified by the model as excluded (approximately 84% of all samples), followed by inflamed (approximately 15%). The model identified very few samples as desert (approximately 1%) (Figure 3)
- Association between immune phenotype and the gold standard CD8 IHC score at the tumor core showed that samples with the inflamed phenotype had higher CD8 scores at the tumor core than samples with the excluded phenotype (Mann-Whitney p<0.026) (Figure 4)
- Inflamed vs excluded slides show the difference in relative abundance of lymphocytes in tumor compartments (Figure 5)


#### Table 1. Frames-based analysis of model performance PathAl algorithm Pearson Cell model class estimate (95% CI)† estimate (95% CI)\* 0.89 (0.84-0.93) 0.82 (0.77-0.87) 0.89 (0.86-0.92) Lymphocyte 0.90 (0.87-0.93) 0.71 (0.63-0.78) 0.74 (0.66-0.80) 0.65 (0.53-0.74) 0.73 (0.66-0.79) Granulocyte


0.53 (0.42-0.63)


0.44 (0.34-0.52)


\*Annotator vs consensus. †Model vs consensus Figure 2. Model Performance

Macrophage









Confusion matrices	Model	Aggregated annotator
Accurate predictions, %	0.8647	0.8220
Innaccurate predictions, %	0.1353	0.1780
Concordance with consensus	Model	Average annotator
Cohen ĸ	0.816	0.680
		0.761

Figure 3. Distribution of H&E slide—level immune phenotypes across trial arms






Figure 5. Machine learning model-generated tissue and cell overlays of WSI with inflamed vs excluded immune





PathAI model-generated tissue- and cell-level overlays. (A) Overlays on WSI with inflamed phenotype. (B) Overlavs on WSI with excluded phenotype. Tissue-level overlays show model predictions for regions of cancer epithelium (red) and cancer stroma (orange). Cell-level overlays show model predictions for lymphocytes (green).

Excluded


0.00055

Figure 4. Association between digital immune phenotype

Avelumab + BSC Trial Arm

and CD8 IHC score

Excluded H&E slide-level digital immune phenotype



H&E slide-level digital immune phenotype BSC, best supportive care; H&E, hematoxylin and eosin.

 Summary of product characteristics. Merck Europe BV, Amsterdam, the Netherlands, an affiliate of Merck Europe BV, Amsterdam, the Netherlands, an affiliate of Merck Europe BV, Amsterdam, the Netherlands, an affiliate of Merck Europe BV, Amsterdam, the Netherlands, an affiliate of Merck Europe BV, Amsterdam, the Netherlands, an affiliate of Merck Europe BV, Amsterdam, the Netherlands, an affiliate of Merck Europe BV, Amsterdam, the Netherlands, an affiliate of Merck Europe BV, Amsterdam, the Netherlands, an affiliate of Merck Europe BV, Amsterdam, the Netherlands, an affiliate of Merck Europe BV, Amsterdam, the Netherlands, an affiliate of Merck Europe BV, Amsterdam, the Netherlands, an affiliate of Merck Europe BV, Amsterdam, the Netherlands, an affiliate of Merck Europe BV, Amsterdam, the Netherlands, an affiliate of Merck Europe BV, Amsterdam, the Netherlands, an affiliate of Merck Europe BV, Amsterdam, the Netherlands, an affiliate of Merck Europe BV, Amsterdam, the Netherlands, an affiliate of Merck Europe BV, Amsterdam, the Netherlands, an affiliate of Merck Europe BV, Amsterdam, the Netherlands, an affiliate of Merck Europe BV, Amsterdam, the Netherlands Europe BV, Amsterdam, the Netherl Sert en beston, MA, USA. It is an employee and shareholder of Path Al, Inc, Boston, MA, USA. It en beston, MA, USA. It is an employee and shareholder of Path Al, Inc, Boston, MA, USA. It en beston, MA, USA. It is an employee and shareholder of Path Al, Inc, Boston, MA, USA. It is an employee and shareholder in best on the time research was conducted. It is an employee and shareholder of Path Al, Inc, Boston, MA, USA. It is an employee and shareholder in best on the health care business of Merck KGaA, Darmstadt, Germany and a shareholder in best on the health care business of Merck KGaA, Darmstadt, Germany and a shareholder in best on the health care business of Merck KGaA, Darmstadt, Germany and a shareholder in best on the health care business of Merck KGaA, Darmstadt, Germany and a shareholder in best on the health care business of Merck KGaA, Darmstadt, Germany and a shareholder in best on the health care business of Merck KGaA, Darmstadt, Germany and shareholder in best on the health care business of Merck KGaA, Darmstadt, Germany and a shareholder in best of the health care business of Merck KGaA, Darmstadt, Germany and a shareholder in best of the health care business of Merck KGaA, Darmstadt, Germany and a shareholder in best of the health care business of Merck KGaA, Darmstadt and the health care business of the healt Sermany. S Brutus is an employee of the healthcare business of Merck KGaA, Darmstadt, Germany. A Wang is an employee of the healthcare business of Merck KGaA, Darmstadt, Germany. S Brutus is an employee of the healthcare business of Merck KGaA, Darmstadt, Germany. S Brutus is an employee of the healthcare business of Merck KGaA, Darmstadt, Germany. S Brutus is an employee of the healthcare business of Merck KGaA, Darmstadt, Germany. S Brutus is an employee of the healthcare business of Merck KGaA, Darmstadt, Germany. S Brutus is an employee of the healthcare business of Merck KGaA, Darmstadt, Germany. S Brutus is an employee of the healthcare business of Merck KGaA, Darmstadt, Germany. S Brutus is an employee of the healthcare business of Merck KGaA, Darmstadt, Germany. S Brutus is an employee of the healthcare business of Merck KGaA, Darmstadt, Germany. S Brutus is an employee of the healthcare business of Merck KGaA, Darmstadt, Germany. S Brutus is an employee of the healthcare business of Merck KGaA, Darmstadt, Germany. S Brutus is an employee of the healthcare business of Merck KGaA, Darmstadt, Germany. S Brutus is an employee of the healthcare business of Merck KGaA, Darmstadt, Germany. S Brutus is an employee of the healthcare business of Merck KGaA, Darmstadt, Germany. S Brutus is an employee of the healthcare business of Merck KGaA, Darmstadt, Germany. S Brutus is an employee of the healthcare business of Merck KGaA, Darmstadt, Germany. S Brutus is an employee of the healthcare business of Merck KGaA, Darmstadt, Germany. S Brutus is an employee of the healthcare business of Merck KGaA, Darmstadt, Germany. S Brutus is an employee of the healthcare business of Merck KGaA, Darmstadt, Germany. S Brutus is an employee of the healthcare business of Merck KGaA, Darmstadt, Germany. S Brutus is an employee of the healthcare business of Merck KGaA, Darmstadt, Germany. S Brutus is an employee of the healthcare business of Merck KGaA, Darmstadt, Germany. S Brutus is an employee of the healthcare business of Merck KG ACKNOWLEDGMENTS This research was sponsored by the healthcare business of Merck KGaA, Darmstadt, Germany and Pfizer. Editorial support was provided by Clinical Thinking and funded by Clinical Thinking and funded by the healthcare business of Merck KGaA, Darmstadt, Germany and Pfizer. Editorial support was provided by Clinical Thinking and Fizer. Editorial support was provided by Clinical Thinking and Pfizer.